Trial in Progress: A Phase 1b/2 Study of GB5121, a Novel, Highly Selective, Potent, and CNS-Penetrant BTK Inhibitor for Relapsed/Refractory Primary/Secondary CNS Lymphoma and Primary Vitreoretinal Lymphoma (STAR CNS)

SNOASCO – Aug 2022